Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

SNAIL1 employs β-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation.

Freihen V, Rönsch K, Mastroianni J, Frey P, Rose K, Boerries M, Zeiser R, Busch H, Hecht A.

Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32644. [Epub ahead of print]

PMID:
31463973
2.

Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia.

Yu C, Gorantla SP, Müller-Rudorf A, Müller TA, Kreutmair S, Albers C, Jakob L, Lippert LJ, Yue Z, Engelhardt M, Follo M, Zeiser R, Huber TB, Duyster J, Illert AL.

Haematologica. 2019 Aug 8. pii: haematol.2018.212027. doi: 10.3324/haematol.2018.212027. [Epub ahead of print]

3.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7770):E19. doi: 10.1038/s41586-019-1475-x.

PMID:
31367045
4.

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis.

Pantic M, Pfeifer D, Kapp-Schwoerer S, Ihorst G, Becker H, Zeiser R, Duyster J, Schmitt-Graeff A.

Leukemia. 2019 Jul 26. doi: 10.1038/s41375-019-0523-8. [Epub ahead of print] No abstract available.

PMID:
31350530
5.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Erratum in: Nature. 2019 Aug 1;:.

PMID:
31316209
6.

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.

Rudorf A, Müller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, Rückert T, Schmitt-Graeff A, Gengenbacher A, Paschka P, Baldus C, Zeiser R, Vassiliou GS, Bradley A, Duyster J, Illert AL.

Blood. 2019 Jul 25;134(4):383-388. doi: 10.1182/blood.2018883140. Epub 2019 Jun 11.

7.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, Cieri N, Noviello M, Manfredi F, Montaldo E, Ostuni R, Naldini MM, Gentner B, Waterhouse M, Zeiser R, Finke J, Hanoun M, Beelen DW, Gojo I, Luznik L, Onozawa M, Teshima T, Devillier R, Blaise D, Halkes CJM, Griffioen M, Carrabba MG, Bernardi M, Peccatori J, Barlassina C, Stupka E, Lazarevic D, Tonon G, Rambaldi A, Cittaro D, Bonini C, Fleischhauer K, Ciceri F, Vago L.

Nat Med. 2019 Apr;25(4):603-611. doi: 10.1038/s41591-019-0400-z. Epub 2019 Mar 25.

PMID:
30911134
8.

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.

Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, Stölzel F, Altmann H, Bornhäuser M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C.

Nat Commun. 2019 Mar 25;10(1):1065. doi: 10.1038/s41467-019-08871-1.

9.

Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.

Thangavelu G, Lee YC, Loschi M, Schaechter KM, Feser CJ, Koehn BH, Nowak EC, Zeiser R, Serody JS, Murphy WJ, Munn DH, Chambon P, Noelle RJ, Blazar BR.

J Immunol. 2019 May 1;202(9):2795-2805. doi: 10.4049/jimmunol.1800899. Epub 2019 Mar 18.

PMID:
30885956
10.

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1450-1455. doi: 10.1016/j.bbmt.2019.03.003. Epub 2019 Mar 13.

PMID:
30876928
11.

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.

Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D.

Bone Marrow Transplant. 2019 Mar 4. doi: 10.1038/s41409-019-0498-0. [Epub ahead of print]

PMID:
30833743
12.

Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.

Prestipino A, Zeiser R.

Sci Transl Med. 2019 Feb 6;11(478). pii: eaav4810. doi: 10.1126/scitranslmed.aav4810. Review.

PMID:
30728286
13.

Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD.

Köhler N, Zeiser R.

Front Immunol. 2019 Jan 17;9:3179. doi: 10.3389/fimmu.2018.03179. eCollection 2018. Review.

14.

B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.

Köhler M, Ehrenfeld S, Halbach S, Lauinger M, Burk U, Reischmann N, Cheng S, Spohr C, Uhl FM, Köhler N, Ringwald K, Braun S, Peters C, Zeiser R, Reinheckel T, Brummer T.

Oncogene. 2019 Feb;38(8):1324-1339. doi: 10.1038/s41388-018-0663-8. Epub 2019 Jan 18.

PMID:
30659267
15.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016. Epub 2019 Jan 15. Review.

PMID:
30658222
16.

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P, Frei AP.

Eur J Immunol. 2019 Mar;49(3):462-475. doi: 10.1002/eji.201847862. Epub 2019 Jan 9.

PMID:
30578679
17.

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.

Zeiser R, Vago L.

Blood. 2019 Mar 21;133(12):1290-1297. doi: 10.1182/blood-2018-10-846824. Epub 2018 Dec 21. Review.

PMID:
30578254
18.

Editorial: Non-coding RNAs and Graft versus Host Disease.

Reddy P, Zeiser R.

Front Immunol. 2018 Nov 20;9:2713. doi: 10.3389/fimmu.2018.02713. eCollection 2018. No abstract available.

19.

Biology-driven developments in the therapy of acute graft-versus-host disease.

Zeiser R.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):236-241. doi: 10.1182/asheducation-2018.1.236. Review.

PMID:
30504316
20.

Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells.

Tugues S, Amorim A, Spath S, Martin-Blondel G, Schreiner B, De Feo D, Lutz M, Guscetti F, Apostolova P, Haftmann C, Hasselblatt P, Núñez NG, Hottiger MO, van den Broek M, Manz MG, Zeiser R, Becher B.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaat8410. doi: 10.1126/scitranslmed.aat8410.

PMID:
30487251
21.
22.

miR-146a Controls Immune Response in the Melanoma Microenvironment.

Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S, Schmidt D, Falk M, Andrieux G, Pfeifer D, Dierbach H, Schmitt-Graeff A, Meiss F, Boerries M, Zeiser R.

Cancer Res. 2019 Jan 1;79(1):183-195. doi: 10.1158/0008-5472.CAN-18-1397. Epub 2018 Nov 13.

23.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

24.

Cobimetinib (GDC-0973, XL518).

Andrlová H, Zeiser R, Meiss F.

Recent Results Cancer Res. 2018;211:177-186. doi: 10.1007/978-3-319-91442-8_12. Review.

PMID:
30069767
25.

Vismodegib.

Meiss F, Andrlová H, Zeiser R.

Recent Results Cancer Res. 2018;211:125-139. doi: 10.1007/978-3-319-91442-8_9. Review.

PMID:
30069764
26.

Trametinib (GSK1120212).

Zeiser R, Andrlová H, Meiss F.

Recent Results Cancer Res. 2018;211:91-100. doi: 10.1007/978-3-319-91442-8_7. Review.

PMID:
30069762
27.

Ruxolitinib.

Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R.

Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6.

PMID:
30069628
28.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
29.

P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis.

Rennert L, Zschiedrich S, Sandner L, Hartleben B, Cicko S, Ayata CK, Meyer C, Zech A, Zeiser R, Huber TB, Idzko M, Grahammer F.

Front Immunol. 2018 Jul 16;9:1589. doi: 10.3389/fimmu.2018.01589. eCollection 2018.

30.

Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.

Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, Marks R, Prasse A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2277-2284. doi: 10.1016/j.bbmt.2018.06.024. Epub 2018 Jun 28.

PMID:
29964193
31.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
32.

Detection of major histocompatibility complex molecules in processed allogeneic bone blocks for use in alveolar ridge reconstruction.

Fretwurst T, Gad LM, Steinberg T, Schmal H, Zeiser R, Amler AK, Nelson K, Altmann B.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Mar 20. pii: S2212-4403(18)30054-3. doi: 10.1016/j.oooo.2018.01.018. [Epub ahead of print]

PMID:
29571656
33.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

34.

Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.

Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, Zeiser R.

Blood. 2018 Apr 19;131(16):1858-1869. doi: 10.1182/blood-2017-10-812891. Epub 2018 Feb 20.

35.

B-cell targeting in chronic graft-versus-host disease.

Zeiser R, Sarantopoulos S, Blazar BR.

Blood. 2018 Mar 29;131(13):1399-1405. doi: 10.1182/blood-2017-11-784017. Epub 2018 Feb 1. Review.

36.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

37.

Acute Graft-versus-Host Disease.

Zeiser R, Blazar BR.

N Engl J Med. 2018 Feb 8;378(6):586. doi: 10.1056/NEJMc1716969. No abstract available.

PMID:
29414273
38.

The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease.

Chen S, Zeiser R.

Front Immunol. 2018 Jan 23;9:4. doi: 10.3389/fimmu.2018.00004. eCollection 2018. Review.

39.

Immune modulatory effects of statins.

Zeiser R.

Immunology. 2018 May;154(1):69-75. doi: 10.1111/imm.12902. Epub 2018 Feb 20. Review.

40.

Introduction to a review series on strategies to improve GVL effects.

Zeiser R.

Blood. 2018 Mar 8;131(10):1039. doi: 10.1182/blood-2017-11-814467. Epub 2018 Jan 22. No abstract available.

41.

Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.

Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV.

Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10.

42.

Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Dec 28;377(26):2565-2579. doi: 10.1056/NEJMra1703472. Review. No abstract available.

PMID:
29281578
43.

Negative regulation of TGF-β1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b.

Witte D, Otterbein H, Förster M, Giehl K, Zeiser R, Lehnert H, Ungefroren H.

Sci Rep. 2017 Dec 11;7(1):17313. doi: 10.1038/s41598-017-15170-6.

44.

MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy.

Pankratz F, Hohnloser C, Bemtgen X, Jaenich C, Kreuzaler S, Hoefer I, Pasterkamp G, Mastroianni J, Zeiser R, Smolka C, Schneider L, Martin J, Juschkat M, Helbing T, Moser M, Bode C, Grundmann S.

Circ Res. 2018 Feb 2;122(3):417-432. doi: 10.1161/CIRCRESAHA.117.311428. Epub 2017 Dec 5.

PMID:
29208678
45.

Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Zeiser R, Blazar BR.

N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337. Review. No abstract available.

46.

The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.

Weinberg F, Reischmann N, Fauth L, Taromi S, Mastroianni J, Köhler M, Halbach S, Becker AC, Deng N, Schmitz T, Uhl FM, Herbener N, Riedel B, Beier F, Swarbrick A, Lassmann S, Dengjel J, Zeiser R, Brummer T.

EBioMedicine. 2017 Jun;20:79-97. doi: 10.1016/j.ebiom.2017.04.015. Epub 2017 Apr 12.

47.

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.

Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.

48.

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R.

Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.

49.

Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival.

Shahinian JH, Fuellgraf H, Tholen S, Mastroianni J, Knopf JD, Kuehs M, Mayer B, Schlimpert M, Kulemann B, Kuesters S, Hoeppner J, Wellner UF, Werner M, Hopt UT, Zeiser R, Bronsert P, Schilling O.

J Cancer. 2016 Oct 17;7(14):2018-2027. eCollection 2016.

50.

CXCR4 antagonists suppress small cell lung cancer progression.

Taromi S, Kayser G, Catusse J, von Elverfeldt D, Reichardt W, Braun F, Weber WA, Zeiser R, Burger M.

Oncotarget. 2016 Dec 20;7(51):85185-85195. doi: 10.18632/oncotarget.13238.

Supplemental Content

Loading ...
Support Center